Biotechnology

HUALAN BIOLOGICAL

HUALAN BIOLOGICAL released FY2026 Q1 earnings on April 26 During-Market (BJT), actual revenue CNY 762.11 M (forecast CNY 910.99 M), actual EPS CNY 0.126 (forecast CNY 0.17)

HUALAN BIOLOGICAL to release FY2026 Q1 earnings report on April 27 During-Market (BJT), forecast revenue CNY 910.99 M, EPS CNY 0.17

HUALAN BIOLOGICAL released FY2025 Q4 earnings on March 27 After-Market (BJT), actual revenue CNY 1.216 B (forecast CNY 1.317 B), actual EPS CNY 0.0857 (forecast CNY 0.24)

HUALAN BIOLOGICAL released FY2025 earnings on March 27 After-Market (BJT), actual revenue CNY 4.595 B (forecast CNY 4.743 B), actual EPS CNY 0.5151 (forecast CNY 0.6581)

HUALAN BIOLOGICAL to Release FY2025 Earnings on March 28 After-Market (BJT), Forecast Revenue CNY 4.743 B, EPS CNY 0.6581

HUALAN BIOLOGICAL released FY2025 9 Months Earnings on October 29 After-Market (BJT), actual revenue CNY 3.379 B, actual EPS CNY 0.4287

HUALAN BIOLOGICAL released FY2025 Q3 earnings on October 29 After-Market (BJT), actual revenue CNY 1.581 B (forecast CNY 2.114 B), actual EPS CNY 0.1466 (forecast CNY 0.31)

HUALAN BIOLOGICAL to Release FY2025 Q3 Earnings on October 30 After-Market (BJT), Forecast Revenue CNY 2.114 B, EPS CNY 0.31

HUALAN BIOLOGICAL released FY2025 Q2 earnings on August 27 After-Market (BJT), actual revenue CNY 930.59 M (forecast CNY 1.037 B), actual EPS CNY 0.1108 (forecast CNY 0.11)

HUALAN BIOLOGICAL released FY2025 Semi-Annual Earnings on August 27 After-Market (BJT), actual revenue CNY 1.798 B, actual EPS CNY 0.2821

Hualan Biological FY2025 Semi-Annual Earnings Release on August 29, 2025 (BJT)

Huaron Biologic's Progress in Innovative Drug R&D and Production

Hualan Biological's Subsidiary Receives Clinical Trial Approval for Dry B-Type Haemophilus Influenzae Vaccine

Huaron Biotech's Secretary Responds to Investors on Product Development and Shareholder Status

Huaxia Biological Plans to Increase Investment in Wholly-Owned Subsidiary by 200 Million Yuan

Huaxia Biological's trivalent influenza vaccine removed from WHO prequalification list

Huaron Biologics Obtains Patent for Plasma Cryopreservation Cold Storage

Huaxia Biological Secretary Responds to Investors' Questions on Company's Financial and Business Status

Huaron Biologics Obtained Single Plasma Collection License

Hualan Bio Avastin Sales Strong in Q1 2025

002007

301207

In the afternoon, there was a partial fluctuation in the anti-influenza concept, with Hualan Vac rising over 10%. Zhifei Biological, Teva Pharmaceutical, Jinshi Yayao, and Hendi Pharmaceutical quickly surged

Zhitong

Hualan Vac

Afternoon flu concept shows partial fluctuations, Hualan Vac rises over 10%

According to Wind data, today 9 A-shares are undergoing equity registration, all of which plan to distribute dividends, with the registration date set for October 24th. Among them, Hualan Vac, HUALAN BIOLOGICAL, and Xizhuang Co., Ltd. have the highest dividend payouts, at 6.00 yuan, 5.00 yuan, and 3.00 yuan per 10 shares, respectively. In addition, 12 stocks have announced dividend plans, with Wireless Media, Baolidi, and Songzhi Co., Ltd. having the highest dividend payouts, at 3.75 yuan, 2.0 yuan, and 1.5 yuan per 10 shares, respectively

Overview of A-share dividends and stock distributions: 9 stocks have their equity registration today

002581

In September, multiple provinces including Beijing and Zhejiang have successively launched this year's influenza vaccine vaccination work. A piece of news stating that "the unit price of the public-funded influenza vaccine has dropped to 5.5 yuan" has attracted industry attention. On September 1 and 2, the National Public Resources Trading Platform (Beijing) successively released the winning announcements for the 2025 Beijing influenza vaccine immunization and non-immunization procurement projects, with HUALAN BIOLOGICAL, Shanghai Institute of Biological Products, and Beijing Kexing being awarded the "immunization" project. (Yicai)

36Kr

Sinobioway Medicine

The flu vaccine has a "freezing point price" of 5.5 yuan

HUALAN BIOLOGICAL released its semi-annual report for 2025, reporting an operating income of 1.798 billion yuan during the reporting period, a year-on-year increase of 8.80%; net profit attributable to shareholders of the parent company was 516 million yuan, a year-on-year increase of 17.19%; net profit excluding non-recurring gains and losses was 484 million yuan, a year-on-year increase of 33.41%; basic earnings per share were 0.2824 yuan

HUALAN BIOLOGICAL released its performance for the first half of the year, with a net profit attributable to the parent company of 516 million yuan, a year-on-year increase of 17.19%

According to Tianyancha's business information, recently, HUALAN BIOLOGICAL Engineering Co., Ltd. underwent a business change, with its registered capital increased from 200 million RMB to 300 million RMB, an increase of 50%. The company was established in June 2013, with An Kang as the legal representative. Its business scope includes research, development, production, and sales of biological products, technology transfer, inspection and testing, and agency processing services; biopharmaceutical technology consulting, and import and export of goods or technology. Shareholder information shows that the company is held by An Kang and HUALAN BIOLOGICAL, with shares of 60% and 40%, respectively

HUALAN BIOLOGICAL's subsidiary genetic engineering company increased its capital to 300 million, an increase of 50%

688185

06185

603392

300142

Zhonghui Biological has performed well in the high-end vaccine sector but still faces the dilemma of industry competition. Although the company has a commercialized vaccine, the market holds a cautious attitude towards its future growth potential, resulting in the IPO subscription costs being unattractive to ordinary investors. In 2023, IPO activities for healthcare companies in Hong Kong were active, but the overall fundraising level was lower than in 2021, reflecting investors' rationality and caution

CanSinoBIO

CANSINOBIO

Wantai Biological

WALVAX

Zhonghui Biological: Holding high-end vaccine single product performance surges, yet still struggling to break the industry's involution dilemma?

As global markets see positive corporate earnings and rising consumer inflation, the tech sector is highlighted, with the Nasdaq Composite reaching new highs. Key high-growth tech companies include Gold Circuit Electronics, Shanghai Huace Navigation Technology, and Pharma Mar, showcasing strong revenue and earnings growth. Notable picks like Shanghai Film and HAND Enterprise Solutions demonstrate resilience and adaptability, with projected earnings growth outpacing market averages. Hualan Biological Vaccine is also positioned for significant growth, focusing on R&D and operational improvements. Investors are encouraged to explore these opportunities in the tech sector.

Simplywall

High Growth Tech Stocks To Explore In July 2025

HUALAN BIOLOGICAL announced that it will increase its investment in its affiliated company HUALAN Gene by 200 million yuan. HUALAN Gene currently has a registered capital of 200 million yuan, with HUALAN BIOLOGICAL holding a 40% stake. The gene company plans to raise 500 million yuan, of which 100 million yuan will be used for registered capital and 400 million yuan for capital reserves. After the capital increase, the shareholding ratio of HUALAN BIOLOGICAL and its actual controller Mr. An Kang will remain unchanged

HUALAN BIOLOGICAL plans to increase its investment in its affiliated company HUALAN GENETICS by 200 million yuan

According to the Qichacha APP, recently, Kanghai Yuhang International Trade Co., Ltd. was established, with Han Zhiwei as the legal representative and a registered capital of 5 million yuan. The business scope includes: import and export of pharmaceuticals; sales of daily necessities; wholesale of daily necessities; sales of daily sundries; sales of pharmaceutical special equipment; sales of daily chemical products, etc. Qichacha's equity penetration shows that the company is wholly owned by HUALAN GENETIC ENGINEERING CO., LTD., which is jointly held by Ankang and HUALAN BIOLOGICAL

HUALAN BIOLOGICAL and others established an international trading company in Shanghai

HUALAN BIOLOGICAL's trivalent influenza vaccine has been removed from the latest prequalification list of the World Health Organization. The vaccine received prequalification in 2015, becoming the first domestically produced influenza vaccine to obtain this certification and was included in the procurement plan of relevant United Nations agencies

HUALAN BIOLOGICAL's trivalent influenza vaccine loses World Health Organization prequalification status

HUALAN BIOLOGICAL(002007.SZ)